Depomed Inc. has announced that a clinical trial to evaluate a new delivery and absorption method for a medicine currently used to treat gastroesophageal reflux disorder (GERD) has been completed. Depomed hopes to translate these findings into an oral, controlled-released GERD medicine formula that will specifically treat nocturnal acid breakthrough. Nocturnal acid breakthrough is a condition that the drugmaker feels current therapies do not adequately treat.
Read moreOne way to change health care policy in the United States is to vote for a presidential candidate who supports your plan for medical... Read more »
Many children with severe GERD, food allergies or metabolic disorders have serious problems digesting basic formulas and some even have... Read more »
A recent study presented at the NASPGHAN conference confirms what parents of children with reflux experience every day -- Gastroesophageal... Read more »
This is the letter my girls would have written to me before they were born to explain their GERD. I have seen other parents write... Read more »
It took eleven long months for Jacob to be diagnosed with Gastroesophageal Reflux Disease (GERD). His mom, Meg contacted me recently to... Read more »
The U.S. Food and Drug Administration (FDA) approved NEXIUM® delayed release capsules in children ages 12 to 17 for the short-term treatment of... Read more »
Source: ADAM Encyclopedia
Acid suppression continues to be the mainstay for treating GERD that does not respond to lifestyle changes and treatment. The aim of drug therapy is... Read more »